Condition: Acute Myeloid Leukemia · Sponsor: Centre Hospitalier Universitaire, Amiens
Neutropenia after induction or consolidation therapy for acute myeloid leukemia (AML) patients is associated with a high morbi-mortality rates, especially due to infectious complications. These are managed according to international recommandations (ECIL and IDSA) with antibiotherapy and antifungal strategy. Although the patients suffer of digestive symptoms, intestinale complications are really less explored. Neutropenic enterocolitis (NE), cytomegalovirus (CMV) colitis, Clostridium difficile colitis, specific lesion, ischemic colitis are not well-known. No prospective study evaluate NE and these digestive complications which have high morbi-mortality rates.
This description comes directly from the study's public registry record.
Delphine LEBON, Doctor · 0033 3 22 45 59 17 · lebon.delphine@chu-amiens.fr
Always discuss trial participation with your own doctor first.
| CHU Amiens-Picardie | Amiens, France | Not Yet Recruiting |
| CHU de Caen | Caen, France | Not Yet Recruiting |
| Henri Becquerel Center | Rouen, France | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03450512